Shares of leading cardiovascular and medsurg (medical-surgical) technologies provider Boston Scientific (NYSE: BSX) are down 16% as of noon ET on Wednesday, following its fourth-quarter earnings ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024 at Alumni Stadium in ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was ...

Feb 4 (Reuters) - Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, ‌overshadowing a strong fourth-quarter performance and sending ...

Boston Scientific (BSX) lost ~9% in the premarket on Wednesday after the MedTech giant indicated an underwhelming outlook for 2026 with its Q4 2025 results, which, however, beat Street forecasts ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

Shares of Boston ScientificBSX took a beating Wednesday after sales of its most hyped segment, electrophysiology, missed Wall Street's fourth-quarter expectations. Electrophysiology tools — like ...

Feb 4 (Reuters) - Boston Scientific (BSX.N), opens new tab on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...